Skip to main content

Table 1 Patient characteristics of tumors and treatment

From: Impact of planning organ at risk volume margins and matching method on late gastrointestinal toxicity in moderately hypofractionated IMRT for locally advanced pancreatic ductal adenocarcinoma

Characteristic

Protocol A

Protocol B

p-value

Number of patients

23

14

 

Age (median, range [years])

70 (53–83)

72.5 (48–86)

0.61

Gender (male/female)

15/8

6/8

0.31

PS (0/1/2)

13/9/1

10/4/0

 

Tumor location (head/body-tail)

9/14

10/4

0.091

Pretreatment CA19-9[U/ml]

298 (8.7–2368)

280 (6.1–2715)

0.96

GTV (median, range[cm3])

31.46 (10.8–89.6)

21.65 (2.4–86.5)

0.11

PTV (median, range[cm3])

212.6 (146.2–483.4)

193 (129.4–452.3)

0.38

Overlap* (median, range[cm3])

43.8 (12.4–105.2)

33.8 (9.7–85.4)

0.067

Induction Chemo-regimen (GEM/S1/ mFOLFIRINOX/GnP)

12/2/3/6

7/2/0/5

 

Concurrent Chemo-regimen (GEM/S1)

19/4

12/2

1

PPI prescription**

21

14

0.51

NSAIDs prescription ***

3

2

1

  1. Abbreviations: PS, performance status; GTV, gross tumor volume; PTV, planning target volume; GEM, gemcitabine; mFOLFIRINOX, modified FOLFIRINOX; GnP, gemcitabine plus nab-paclitaxel; PPI, proton pump inhibitor; NSAIDs, non-steroidal anti-inflammatory drugs
  2. Note: *Overlap indicates overlapping areas of PTV and PRV
  3. **PPI prescription was defined at least up to 3 months from RT
  4. ***NSAIDs prescription was defined at least > 180 mg/day for more than one week